BLACK DIAMOND THERAPEUTICS, INC. Operating Lease, Expense
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Operating Lease, Expense of $5.28 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-03-16
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, expense for fiscal 2025 was $5.28M, a 0.08% increase from fiscal 2024.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, expense for fiscal 2024 was $5.28M, a 1.09% increase from fiscal 2023.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, expense for fiscal 2023 was $5.22M, a 2.32% decline from fiscal 2022.
- BLACK DIAMOND THERAPEUTICS, INC. operating lease, expense for fiscal 2022 was $5.34M, a 36.24% increase from fiscal 2021.
| Period end | Operating Lease, Expense 12 month |
|---|---|
| 2025-12-31 | $5.28M 10-K · filed 2026-03-16 |
| 2024-12-31 | $5.28M 10-K · filed 2026-03-16 |
| 2023-12-31 | $5.22M 10-K · filed 2025-03-06 |
| 2022-12-31 | $5.34M 10-K · filed 2024-03-12 |
| 2021-12-31 | $3.92M 10-K · filed 2023-03-09 |
| 2020-12-31 | $1.54M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |